The First International Symposium on Pheochromocytoma ... the most accurate screening approach, was recommended as the first-line test for diagnosis; reference intervals should favor sensitivity ...

“Pheochromocytoma and paraganglioma are rare tumors that ... By addressing barriers to clinical trial participation, screening and treatment, we work with urgency to reduce disparities and help ensure ...

the current WHO nomenclature reserves the term 'pheochromocytoma' for paragangliomas of adrenal origin Measurements of plasma or urinary fractionated metanephrines are the most accurate screening ...

A laparoscope is placed into the surgical incisions to project the body's structures on a screen. Rather than seeing the internal ... Laparoscopic versus open surgery for pheochromocytoma: a ...

focused on the evaluation of postoperative management of patients with pheochromocytoma assessing hemodynamic ... cortisol is not sufficiently sensitive or specific to be used for screening patients ...

Suicide is one of the leading causes of death among youth in the United States, and pediatricians play an integral role in ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.

The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.

Not all screen time is created equally. Experts explain why quality matters more than quantity and how parents can rethink their rules for devices. A young child watches cartoons on a laptop at home.

Scientists have created a new low-cost, fast response sensor to detect lung cancer biomarkers, paving the way for the development of screening devices to spot the disease even before symptoms occur.

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.